Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Clinician-Selected FSH Starting Dose and Mature Oocyte Yield in Predicted Poor Responders (OPTIMAL-DOSE)

17. november 2026 oppdatert av: Goksu Goc, American Hospital 2 Kosovo

Association of Clinician-Selected FSH Starting Dose With Mature Oocyte Yield in Women With Predicted Poor Ovarian Response: The OPTIMAL-DOSE Prospective Cohort Study

This is a single-centre, prospective, non-interventional (observational) cohort study examining the association between the clinician-selected starting dose of follicle-stimulating hormone (FSH) and the yield of mature metaphase II (MII) oocytes in women with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number [POSEIDON] group 3 or 4) undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) with a gonadotropin-releasing hormone (GnRH) antagonist protocol. The FSH dose is chosen by the treating physician as part of routine care; the study does not allocate, randomize, or change treatment. The primary outcome is the number of MII oocytes per initiated index cycle. Because dosing is not randomized, analyses are adjusted for measured confounders and address confounding by indication.

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Randomized evidence in predicted poor responders (a randomized trial in predicted poor responders and the 2024 Cochrane review of individualised gonadotropin dosing) does not show improved live birth from higher follicle-stimulating hormone (FSH) dosing, so this cohort is not designed to establish comparative efficacy; its contribution is a description of real-world dose-response patterns and local gonadotropin use and cost. Consecutive eligible women are enrolled after informed consent for data use, each contributing one index cycle. The exposure is the clinician-selected starting FSH dose, analysed as a continuous variable (per 75 international units [IU]), with categories of 150 IU or less versus more than 150 IU reported descriptively and in sensitivity analyses. The primary analysis is an adjusted negative-binomial regression of the metaphase II (MII) oocyte count on exposure, with adjusted means obtained by marginal standardization and an overlap-weighted propensity analysis as sensitivity. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statements.

Studietype

Observasjonsmessig

Registrering (Antatt)

160

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Pristina, Kosovo, 10000
        • American Hospital Kosova
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 42 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Consecutive women aged 18 to 42 years with predicted poor ovarian response (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 or 4: anti-Mullerian hormone below 1.2 ng/mL and/or antral follicle count below 5) undergoing a gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care at American Hospital Kosova, each contributing one index cycle.

Beskrivelse

Inclusion Criteria:

  1. Woman aged 18 to 42 years.
  2. Predicted poor ovarian response, Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) group 3 (under 35 years) or group 4 (35 years or older): anti-Mullerian hormone (AMH) below 1.2 ng/mL and/or antral follicle count (AFC) below 5 (both ovaries combined).
  3. Planned gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle as part of routine clinical care.
  4. First eligible (index) cycle during the study period; both ovaries present.
  5. Written informed consent for data collection and processing.

Exclusion Criteria:

  1. Predicted normal or high ovarian reserve (AMH 1.2 ng/mL or higher and AFC 5 or higher).
  2. Non-antagonist protocol (for example, long GnRH-agonist).
  3. Oocyte-donation or fertility-preservation (egg-freezing) cycle.
  4. A prior cycle of the same woman already enrolled in the study.
  5. Inability to provide informed consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Lower starting dose (150 international units [IU] or less)

Women whose treating physician chose a starting daily follicle-stimulating hormone (FSH) dose of 150 international units (IU) or less as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Higher starting dose (more than 150 IU)

Women whose treating physician chose a starting daily FSH dose of more than 150 IU (typically 225 IU) as part of routine clinical care (observed, not assigned by the study).

FSH administered per routine clinical practice; the starting dose is selected by the treating physician (observed exposure, not assigned by the study). Starting dose is analysed continuously (per 75 IU), with categories of 150 IU or less versus more than 150 IU reported descriptively.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of mature metaphase II (MII) oocytes retrieved
Tidsramme: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Number of metaphase II (MII) oocytes retrieved per initiated index ovarian stimulation cycle, assessed by the embryologist at a standardized time after oocyte retrieval. Compared across the clinician-selected starting-dose exposure using adjusted analysis (associations, not causal effects). Cycles cancelled before oocyte retrieval contribute zero MII oocytes in the initiated-cycle analysis. Oocytes matured in vitro are excluded from the primary count.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Total follicle-stimulating hormone (FSH) activity administered
Tidsramme: From the first to the last day of ovarian stimulation (up to 21 days)

Total follicle-stimulating hormone (FSH) activity administered during the index stimulation cycle, in international units (IU), by observed starting-dose exposure. FSH activity is recorded separately from luteinizing hormone (LH) and human chorionic gonadotropin (hCG) activity.

From the first to the last day of ovarian stimulation (up to 21 days)
Gonadotropin medication cost
Tidsramme: From the first to the last day of ovarian stimulation (up to 21 days)

Cost of the gonadotropin medication used during the stimulation cycle, in euros (EUR), calculated using a pre-specified standardized unit-price table, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Total number of oocytes retrieved
Tidsramme: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Total number of oocytes retrieved at oocyte pick-up per initiated index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Oocyte maturity rate
Tidsramme: On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)

Ratio of the number of metaphase II (MII) oocytes to the total number of oocytes retrieved in the index cycle, by observed starting-dose exposure.

On the day of oocyte retrieval (up to 21 days after the start of ovarian stimulation)
Cycle cancellation before oocyte retrieval
Tidsramme: From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)

Whether the initiated index cycle was cancelled before oocyte retrieval, by observed starting-dose exposure.

From the first day of ovarian stimulation to the planned day of oocyte retrieval (up to 21 days)
Duration of ovarian stimulation
Tidsramme: From the first to the last day of ovarian stimulation (up to 21 days)

Number of days of ovarian stimulation during the index cycle, by observed starting-dose exposure.

From the first to the last day of ovarian stimulation (up to 21 days)
Number of normally fertilised oocytes with two pronuclei (2PN)
Tidsramme: At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)

Number of oocytes showing two pronuclei (2PN) at the fertilisation check in the index cycle, by observed starting-dose exposure.

At the fertilisation check, 1 day after oocyte retrieval (up to 22 days after the start of ovarian stimulation)
Number of usable embryos
Tidsramme: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle that are transferred, cryopreserved or biopsied, meeting the minimum grade of the pre-specified laboratory standard, by observed starting-dose exposure. Each embryo is counted once.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)
Number of blastocysts
Tidsramme: Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Number of embryos from the index cycle reaching the blastocyst stage, by observed starting-dose exposure.

Up to 6 days after oocyte retrieval (up to 27 days after the start of ovarian stimulation)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Live birth (exploratory)
Tidsramme: Up to 12 months after the start of ovarian stimulation

Delivery of at least one live-born infant, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome and it is highly susceptible to confounding by indication. Reported descriptively.

Up to 12 months after the start of ovarian stimulation
Clinical pregnancy (exploratory)
Tidsramme: At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Presence of an intrauterine gestational sac on ultrasound after the first fresh or frozen embryo transfer from the index cycle, recorded per initiated index cycle and per transfer. Exploratory only; the study is not powered for this outcome. Reported descriptively.

At 7 weeks of gestation (approximately 5 weeks after the first embryo transfer)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

1. oktober 2028

Studiet fullført (Antatt)

1. august 2029

Datoer for studieregistrering

Først innsendt

11. november 2026

Først innsendt som oppfylte QC-kriteriene

17. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • OPTIMAL-DOSE-OBS-2026-001

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .